Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone problems news

Show

From To
A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

Published
19 hours ago
From
Los Angeles Times
HIV-infected young males have higher rates of bone loss than females

Accumulating evidence suggests that rates of low bone mass are greater in HIV-infected males than in females. Researchers led by Grace Aldrovandi, MD, chief of the Division of Infectious Diseases at Children's Hospital Los Angeles, studied 11 biomarkers associated with inflammation, bone loss and/or bone formation in about 450 individuals -- assessed by sex and HIV status -- to try to determine causes of this differential bone loss.

Published
11 March 2016
From
Eurekalert Medicine & Health
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched

Published
25 February 2016
By
Liz Highleyman
Bone density recovers quickly after stopping PrEP

Bone mineral density recovers within six months of stopping pre-exposure prophylaxis (PrEP) containing tenofovir, Bob Grant of the University of California, San Francisco reported on behalf of

Published
24 February 2016
By
Keith Alcorn
Tenofovir treatment raises the risk of broken bones

Treatment containing tenofovir is associated with a higher risk of bone fractures in people living with HIV, but a single infusion of zoledronic acid, a drug used in

Published
23 February 2016
By
Keith Alcorn
Free new tool for health providers to assist physical rehabilitation in people living with HIV

The free website, entitled "How Rehabilitation Can Help People Living with HIV in Sub-Saharan Africa: An Evidence-Informed Tool for Rehab Providers", was adapted from a Canadian resource and is also downloadable for use on paper. It's designed to be a one-stop resource for physiotherapists, occupational therapists and other health workers who can quickly and easily research the most common HIV-related disabilities, and find evidence-based rehabilitation solutions

Published
02 December 2015
From
Eurekalert Medicine & Health
START sub-study shows more bone loss with earlier HIV treatment

Participants who started antiretroviral therapy (ART) soon after HIV diagnosis in the large START trial showed a greater decrease in bone density at the hip and spine

Published
27 October 2015
By
Liz Highleyman
Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety

A single-tablet regimen containing the new tenofovir alafenamide (TAF) – to be marketed as Genvoya – suppressed HIV as well as a co-formulation containing the older tenofovir

Published
25 October 2015
By
Liz Highleyman
Modest bone loss seen in young men taking Truvada for pre-exposure prophylaxis

Young men participating in a pre-exposure prophylaxis (PrEP) demonstration project experienced modest but significant bone loss after starting Truvada, according to findings presented yesterday to a joint session

Published
22 October 2015
By
Liz Highleyman
TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

Published
12 October 2015
From
Monthly Prescribing Reference
← First12345...10Next →

Filter by country